HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lacosamide as a new treatment option in status epilepticus.

Abstract
Status epilepticus is among the most common neurologic emergencies, with a mortality rate of up to 20%. The most important therapeutic goal is fast, effective, and well-tolerated cessation of status epilepticus. Intravenous phenytoin/fosphenytoin, phenobarbital, or valproate is the current standard treatment after failure of benzodiazepines. Lacosamide as a new antiepileptic drug has been available as an intravenous solution since 2009. To date, PubMed lists 19 studies (10 single case reports and 9 case series), reporting a total of 136 episodes of refractory status epilepticus (50% nonconvulsive status epilepticus, 31% focal status epilepticus, and 19% convulsive status epilepticus) treated with lacosamide. The most often used bolus dose was 200-400 mg over 3-5 min. The overall success rate was 56% (76/136). Adverse events (AEs) were reported in 25% (34/136) of patients: mild sedation in 25 cases, 1 patient with possible angioedema, 2 with allergic skin reaction, 4 with hypotension, and 1 with pruritus. One patient developed a third-degree atrioventricular (AV) block and paroxysmal asystole. Overall, the rate of AEs was low. Current evidence on the use of intravenous lacosamide in acute seizures and status epilepticus is restricted to retrospective case reports and case series (class IV). Further prospective studies to inform clinicians are necessary.
AuthorsJulia Höfler, Eugen Trinka
JournalEpilepsia (Epilepsia) Vol. 54 Issue 3 Pg. 393-404 (Mar 2013) ISSN: 1528-1167 [Electronic] United States
PMID23293881 (Publication Type: Journal Article, Review)
CopyrightWiley Periodicals, Inc. © 2013 International League Against Epilepsy.
Chemical References
  • Acetamides
  • Anticonvulsants
  • Lacosamide
Topics
  • Acetamides (administration & dosage)
  • Administration, Intravenous
  • Anticonvulsants (administration & dosage)
  • Humans
  • Lacosamide
  • Retrospective Studies
  • Status Epilepticus (drug therapy, epidemiology, physiopathology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: